Search
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt gained approval by European Commission in March 2009. … Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity.
Chondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceuticalDepending on the predominating disaccharide unit, it will present different biological activities.
Mixtures: Gluco-con capsules, GLUCOSAMINA CON CONDROITINA 500/400 MG CAPSULACategories: Antiinflammatory and Antirheumatic Products, Non-SteroidsVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242277] It results from a gain-of-function missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and in length. … Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment
Categories: Drugs for Treatment of Bone Diseases, Drugs Affecting Bone Structure and MineralizationGlyburide
go.drugbank.com/drugs/DB01016ApprovedInvestigational[A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] … [L8123] Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.
Mixtures: MELLIMET G ® TABLETAS RECUBIERTAS CON PELÍCULA 500MG + 2.5 MGTriclosan
go.drugbank.com/drugs/DB08604ApprovedAn aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group. It is widely used as a preservative and antimicrobial agent in personal care products such as soaps, skin creams, t...
Mixtures: FLUOTOPIC CON FLUORProducts: Bob Barker Antibacterial Bar, Ben E. Keith Foaming Antibacterial Hand CleanerReslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalApproved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion. … Cinqair is indicated as an add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigational[L44381] It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma _in situ_ (CIS) … Most patients with this condition undergo radical cystectomy since other non-surgical treatments are far less effective.
Oxaprozin
go.drugbank.com/drugs/DB00991ApprovedOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticNomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnApproval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets. … The approved application holder removed Merital capsules from the market on January 23, 1986.